Fernando Alcaide

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4357528/publications.pdf

Version: 2024-02-01

92 papers

3,479 citations

136740 32 h-index 55 g-index

99 all docs 99 docs citations 99 times ranked 3319 citing authors

#	Article	IF	CITATIONS
1	Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrobial Agents and Chemotherapy, 1997, 41, 2270-2273.	1.4	146
2	Serious Complications of Bacteremia Caused by Viridans Streptococci in Neutropenic Patients with Cancer. Clinical Infectious Diseases, 2000, 31, 1126-1130.	2.9	136
3	Rapid Detection of Mycobacterium tuberculosis Complex and Rifampin Resistance in Smear-Negative Clinical Samples by Use of an Integrated Real-Time PCR Method. Journal of Clinical Microbiology, 2011, 49, 1137-1139.	1.8	136
4	The Mycobacterium xenopi GyrA protein splicing element: characterization of a minimal intein. Journal of Bacteriology, 1997, 179, 6378-6382.	1.0	131
5	Bacteremia Due to Viridans Streptococci That Are Highly Resistant to Penicillin: Increase Among Neutropenic Patients with Cancer. Clinical Infectious Diseases, 1995, 20, 1169-1173.	2.9	122
6	Bacteremic Pneumonia in Neutropenic Patients With Cancer. Archives of Internal Medicine, 1998, 158, 868.	4.3	118
7	Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies. Journal of Clinical Microbiology, 1997, 35, 1959-1964.	1.8	110
8	In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrobial Agents and Chemotherapy, 1995, 39, 2243-2247.	1.4	107
9	A Global Gene Pool for Highâ€Level Cephalosporin Resistance in CommensalStreptococcusSpecies andStreptococcus pneumoniae. Journal of Infectious Diseases, 1997, 176, 1001-1012.	1.9	106
10	Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 333-343.	2.5	102
11	Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium. Journal of Infectious Diseases, 2012, 206, 1030-1040.	1.9	98
12	Evaluation of the BACTEC MGIT 960 and the MB/BacT Systems for Recovery of Mycobacteria from Clinical Specimens and for Species Identification by DNA AccuProbe. Journal of Clinical Microbiology, 2000, 38, 398-401.	1.8	96
13	Fluoroquinolone Resistance Mutations in the <i>parC</i> , <i>parE</i> , and <i>gyrA</i> Genes of Clinical Isolates of Viridans Group Streptococci. Antimicrobial Agents and Chemotherapy, 1998, 42, 2792-2798.	1.4	94
14	Group B Streptococcal Disease in Nonpregnant Adults: Incidence, Clinical Characteristics, and Outcome. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 168-173.	1.3	84
15	How to: identify non-tuberculous Mycobacterium species using MALDI-TOF mass spectrometry. Clinical Microbiology and Infection, 2018, 24, 599-603.	2.8	83
16	Evaluation of the Xpert MTB/RIF Ultra Assay for Direct Detection of Mycobacterium tuberculosis Complex in Smear-Negative Extrapulmonary Samples. Journal of Clinical Microbiology, 2018, 56, .	1.8	80
17	Effectiveness of an Integrated Real-Time PCR Method for Detection of the Mycobacterium tuberculosis Complex in Smear-Negative Extrapulmonary Samples in an Area of Low Tuberculosis Prevalence. Journal of Clinical Microbiology, 2012, 50, 513-515.	1.8	79
18	High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. Journal of Antimicrobial Chemotherapy, 2001, 47, 87-91.	1.3	62

#	Article	IF	Citations
19	Mycobacteria Clumping Increase Their Capacity to Damage Macrophages. Frontiers in Microbiology, 2016, 7, 1562.	1.5	60
20	Current treatment of nontuberculous mycobacteriosis: an update. Expert Opinion on Pharmacotherapy, 2012, 13, 967-986.	0.9	57
21	In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrobial Agents and Chemotherapy, 1996, 40, 2117-2120.	1.4	56
22	Mycobacterium chelonae tenosynovitis of the hand. Seminars in Arthritis and Rheumatism, 2004, 34, 617-622.	1.6	56
23	Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV,the, 2016, 3, e120-e131.	2.1	53
24	Direct detection in clinical samples of multiple gene mutations causing resistance of Mycobacterium tuberculosis to isoniazid and rifampicin using fluorogenic probes. Journal of Antimicrobial Chemotherapy, 2005, 55, 860-865.	1.3	51
25	Comparative In Vitro Activities of Linezolid, Telithromycin, Clarithromycin, Levofloxacin, Moxifloxacin, and Four Conventional Antimycobacterial Drugs against Mycobacterium kansasii. Antimicrobial Agents and Chemotherapy, 2004, 48, 4562-4565.	1.4	48
26	Characterization of mutations in streptomycin-resistant Mycobacterium tuberculosis clinical isolates in the area of Barcelona. Journal of Antimicrobial Chemotherapy, 2010, 65, 2341-2346.	1.3	45
27	Multicenter Laboratory Evaluation of the MB/BacT Mycobacterium Detection System and the BACTEC MGIT 960 System in Comparison with the BACTEC 460TB System for Susceptibility Testing of Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2007, 45, 1766-1770.	1.8	44
28	Tuberculosis transmission patterns among Spanish-born and foreign-born populations in the city of Barcelona. Clinical Microbiology and Infection, 2010, 16, 568-574.	2.8	44
29	Comparison of the 2-step tuberculin skin test and the quantiFERON-TB gold in-tube test for the screening of tuberculosis infection before liver transplantation. Liver Transplantation, 2011, 17, 1205-1211.	1.3	44
30	Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. European Respiratory Journal, 2009, 33, 148-152.	3.1	42
31	Lab-on-Chip-Based Platform for Fast Molecular Diagnosis of Multidrug-Resistant Tuberculosis. Journal of Clinical Microbiology, 2015, 53, 3876-3880.	1.8	41
32	Usefulness of a New Mycobacteriophage-Based Technique for Rapid Diagnosis of Pulmonary Tuberculosis. Journal of Clinical Microbiology, 2003, 41, 2867-2871.	1.8	32
33	Advances in rapid diagnosis of tuberculosis disease and anti-tuberculous drug resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 34-40.	0.3	32
34	Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array. Journal of Antimicrobial Chemotherapy, 2014, 69, 947-954.	1.3	32
35	In Vitro Activities of the New Ketolide HMR 3647 (Telithromycin) in Comparison with Those of Eight Other Antibiotics against Viridans Group Streptococci Isolated from Blood of Neutropenic Patients with Cancer. Antimicrobial Agents and Chemotherapy, 2001, 45, 624-626.	1.4	31
36	Factors Associated with Differences between Conventional Contact Tracing and Molecular Epidemiology in Study of Tuberculosis Transmission and Analysis in the City of Barcelona, Spain. Journal of Clinical Microbiology, 2009, 47, 198-204.	1.8	29

#	Article	IF	Citations
37	Evolution of cutaneous tuberculosis over the past 30â€fyears in a tertiary hospital on the European Mediterranean coast. Clinical and Experimental Dermatology, 2013, 38, 131-136.	0.6	28
38	Pulmonary Infections with Nontuberculous Mycobacteria, Catalonia, Spain, 1994–2014. Emerging Infectious Diseases, 2018, 24, 1091-1094.	2.0	28
39	Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon- \hat{l}^3 release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagnostic Microbiology and Infectious Disease, 2011, 69, 59-65.	0.8	27
40	Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-γ release assay in patients considered for anti–tumor necrosis factor-α therapy. Diagnostic Microbiology and Infectious Disease, 2011, 71, 57-65.	0.8	27
41	Evaluation of Two Protein Extraction Protocols Based on Freezing and Mechanical Disruption for Identifying Nontuberculous Mycobacteria by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry from Liquid and Solid Cultures. Journal of Clinical Microbiology, 2018, 56, .	1.8	26
42	Evaluation of MALDI Biotyper Interpretation Criteria for Accurate Identification of Nontuberculous Mycobacteria. Journal of Clinical Microbiology, 2020, 58, .	1.8	26
43	Trehalose Polyphleates, External Cell Wall Lipids in Mycobacterium abscessus, Are Associated with the Formation of Clumps with Cording Morphology, Which Have Been Associated with Virulence. Frontiers in Microbiology, 2017, 8, 1402.	1.5	25
44	Incidence and molecular typing of Mycobacterium kansasii in a defined geographical area in Catalonia, Spain. Epidemiology and Infection, 2004, 132, 425-432.	1.0	24
45	Evaluation of the VersaTREK System Compared to the Bactec MGIT 960 System for First-Line Drug Susceptibility Testing of Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2012, 50, 488-491.	1.8	23
46	Molecular Analysis of Isoniazid and Rifampin Resistance in Mycobacterium tuberculosis Isolates Recovered from Barcelona. Microbial Drug Resistance, 2005, 11, 107-114.	0.9	22
47	Increasing isolation of rapidly growing mycobacteria in a low-incidence setting of environmental mycobacteria, 1994–2015. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1425-1432.	1.3	22
48	Use of a Mycobacteriophage-Based Assay for Rapid Assessment of Susceptibilities of Mycobacterium tuberculosis Isolates to Isoniazid and Influence of Resistance Level on Assay Performance. Journal of Clinical Microbiology, 2006, 44, 201-205.	1.8	21
49	Multicentre study on the reproducibility of MALDI-TOF MS for nontuberculous mycobacteria identification. Scientific Reports, 2022, 12, 1237.	1.6	20
50	Absence of Ribosomal RNA of Mycobacterium tuberculosis Complex in Sarcoidosis. Archives of Dermatology, 2005, 141, 57-9.	1.7	19
51	Major differences in organization and availability of health care and medicines for <scp>HIV/TB</scp> coinfected patients across <scp>E</scp> urope. HIV Medicine, 2015, 16, 544-552.	1.0	19
52	Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. PLoS ONE, 2015, 10, e0145380.	1.1	19
53	QuantiFERON-TB Gold In-Tube as a Confirmatory Test for Tuberculin Skin Test in Tuberculosis Contact Tracing: A Noninferiority Clinical Trial. Clinical Infectious Diseases, 2018, 66, 396-403.	2.9	18
54	Microbiological monitoring of flexible bronchoscopes after high-level disinfection and flushing channels with alcohol: Results and costs. Respiratory Medicine, 2015, 109, 1079-1085.	1.3	17

#	Article	IF	CITATIONS
55	Impact of updating the MALDIâ€∓OF MS database on the identification of nontuberculous mycobacteria. Journal of Mass Spectrometry, 2017, 52, 597-602.	0.7	16
56	Inteins in mycobacterial GyrA are a taxonomic character. Microbiology (United Kingdom), 1998, 144, 589-591.	0.7	15
57	Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome. Journal of Clinical Medicine, 2021, 10, 918.	1.0	15
58	GeneXpert® for smear-negative pulmonary tuberculosis: does it play a role in low-burden countries?. Diagnostic Microbiology and Infectious Disease, 2013, 75, 325-326.	0.8	14
59	Mycobacterium kansasii disease among patients infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy. International Journal of Tuberculosis and Lung Disease, 2003, 7, 673-7.	0.6	14
60	Silent Mutation in <i>rpoB</i> Detected from Clinical Samples with Rifampin-Susceptible Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2011, 49, 3722-3722.	1.8	13
61	Antimicrobial resistance of Streptococcus pneumoniae: comparison of the in vitro activity of 16 antibiotics. Current Therapeutic Research, 1996, 57, 57-64.	0.5	11
62	Draft Genome Sequences of Mycobacterium setense Type Strain DSM-45070 and the Nonpathogenic Strain Manresensis, Isolated from the Bank of the Cardener River in Manresa, Catalonia, Spain. Genome Announcements, 2015, 3, .	0.8	11
63	Métodos de determinación de sensibilidad a los antimicrobianos en micobacterias. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 529-535.	0.3	11
64	Detection of streptomycin and quinolone resistance in Mycobacterium tuberculosis by a low-density DNA array. Tuberculosis, 2013, 93, 508-514.	0.8	10
65	Multiple Cranial Osteolytic Lesions due to Mycobacterium kansasii in a Patient with AIDS. Scandinavian Journal of Infectious Diseases, 1998, 30, 305-306.	1.5	9
66	Direct Detection of Mycobacterium tuberculosis Complex in Clinical Samples by a Molecular Method Based on GenoQuick Technology. Journal of Clinical Microbiology, 2012, 50, 2089-2091.	1.8	9
67	Tuberculosis in solid organ transplant patients. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2012, 30, 34-39.	0.3	9
68	Epidemiology of <i>Mycobacterium kansasii</i> . Annals of Internal Medicine, 1999, 131, 310.	2.0	9
69	Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortalityâ€"a multicentre prospective cohort study. BMC Infectious Diseases, 2021, 21, 1038.	1.3	9
70	Molecular techniques in the diagnosis of drug-resistant tuberculosis. Annals of the Academy of Medicine, Singapore, 1997, 26, 647-50.	0.2	8
71	Detection of Minority Variants and Mixed Infections in Mycobacterium tuberculosis by Direct Whole-Genome Sequencing on Noncultured Specimens Using a Specific-DNA Capture Strategy. MSphere, 2021, 6, e0074421.	1.3	8
72	Polyclonality among clinical strains of non-pigmented rapidly growing mycobacteria: phenotypic and genotypic differences and their potential implications. Clinical Microbiology and Infection, 2015, 21, 348.e1-348.e4.	2.8	7

#	Article	IF	CITATIONS
73	QuantiFERON®-TB Gold In-Tube for contact screening in BCG-vaccinated adults: A longitudinal cohort study. PLoS ONE, 2017, 12, e0183258.	1.1	7
74	Use of a commercial double-test tablet (Rosco PGUA/indole) for screening of Escherichia coli. Diagnostic Microbiology and Infectious Disease, 1992, 15, 291-294.	0.8	6
75	Methods for determining the antimicrobial susceptibility of mycobacteria. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 527-533.	0.2	6
76	Diagn \tilde{A}^3 stico microbiol \tilde{A}^3 gico actual de la tuberculosis. Enfermedades Infecciosas Y Microbiolog \tilde{A} a Cl \tilde{A} nica, 2017, 35, 399-402.	0.3	6
77	Healthcare delivery for HIVâ€positive people with tuberculosis in Europe. HIV Medicine, 2021, 22, 283-293.	1.0	6
78	Evaluation of the Fully Automated Chemiluminescence Analyzer Liaison XL for the Performance of the QuantiFERON-TB Gold Plus Assay in an Area with a Low Incidence of Tuberculosis. Journal of Clinical Microbiology, 2021, 59, e0060321.	1.8	6
79	Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study. Microbiology Spectrum, 2021, 9, e0097221.	1.2	6
80	Impaired fitness of Mycobacterium tuberculosis resistant isolates in a cell culture model of murine macrophages. Journal of Antimicrobial Chemotherapy, 2011, 66, 2277-2280.	1.3	5
81	First Human Isolate of Mycobacterium poriferae in the Sputum of a Patient with Chronic Bronchitis. Journal of Clinical Microbiology, 2011, 49, 3107-3108.	1.8	5
82	Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array—authors' response. Journal of Antimicrobial Chemotherapy, 2014, 69, 2299-2300.	1.3	5
83	Detection of interleukin-2 is not useful for distinguishing between latent and active tuberculosis in clinical practice: a prospective cohort study. Clinical Microbiology and Infection, 2016, 22, 1007.e1-1007.e5.	2.8	5
84	Myocardial abscess at a distant zone from the active valvular infection. Journal of Cardiovascular Surgery, 1998, 39, 227-8.	0.3	2
85	First human isolate of Mycobacterium madagascariense in the sputum of a patient with tracheobronchitis. Clinical Chemistry and Laboratory Medicine, 2013, 51, e35-6.	1.4	1
86	Multiplex Real-Time PCR-short TUB Assay for Detection of the Mycobacterium tuberculosis Complex in Smear-Negative Clinical Samples with Low Mycobacterial Loads. Journal of Clinical Microbiology, 2019, 57, .	1.8	1
87	Infectiousness of patients with smear-negative pulmonary tuberculosis, assessed by Real-time Polymerase Chain Reaction, XpertⓇMTB/RIF. Journal of Infection, 2020, 80, 298-300.	1.7	1
88	Fluoroquinolone Resistance Mutations in the DNA Topoisomerase II Genes of Viridans Group Streptococci Clinical Isolates. Drugs, 1999, 58, 125-127.	4.9	0
89	Introduction. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 1.	0.3	0
90	Current microbiological diagnosis of tuberculosis. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 399-402.	0.2	0

#	Article	IF	CITATIONS
91	Utilidad de las técnicas de biologÃa molecular en el diagnóstico de las infecciones cutáneas. Piel, 2019, 34, 40-44.	0.0	O
92	Additional data about the influence of an inhibitory factor on growth of Mycobacterium kansasii in BACTEC 12B medium. Journal of Clinical Microbiology, 1996, 34, 484-484.	1.8	0